Renal interactions in liver dysfunction and failure

Current Opinion in Critical Care

Volumn 19, Issue 2, 2013, Pages 133-141

  Verna, Elizabeth C ^a   Wagener, Gebhard ^b  

^a Center for Liver Disease and Transplantation   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

hepatorenal syndrome; liver kidney axis; liver kidney transplantation; renal biomarkers; renal sparing immunosuppression

Indexed keywords

LOSARTAN; METFORMIN; MIDODRINE; ROSIGLITAZONE; TERLIPRESSIN;

ACUTE KIDNEY FAILURE; CHEMOLUMINESCENCE; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ACUTE KIDNEY INJURY; EARLY DIAGNOSIS; FEMALE; HEPATORENAL SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; RENIN-ANGIOTENSIN SYSTEM; VASOPRESSINS;

EID: 84874786152     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835ebb3a     Document Type: Review

References (47)

1. Serste T, Lebrec D, Valla D, Moreau R. Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites. Acta Gastroenterol Belg 2008; 71:9-14. (Pubitemid 351613479)
2. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236. (Pubitemid 23234041)
3. Martin-Llahi M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140:488-496; e4.
4. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41:1282-1289. (Pubitemid 40770280)
5. Yap S, Park SW, Egan B, Lee HT. Cytokine elevation and transaminitis after laparoscopic donor nephrectomy. Am J Physiol Renal Physiol 2012; 302:F1104-F1111.
6. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
7. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 2012; 9:382-391.
8. Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 31-39.
9. Wadei HM. Hepatorenal syndrome: a critical update. Semin Respir Crit Care Med 2012; 33:55-69.
10. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361:1279-1290.
11. Arroyo V, Bernardi M, Epstein M, et al. Pathophysiology of ascites and functional renal failure in cirrhosis. J Hepatol 1988; 6:239-257.
12. Torres DM, Jones FJ, Shaw JC, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011; 54:1631-1639.
13. Cobden I, Shore A, Wilkinson R, Record CO. Captopril in the hepatorenal syndrome. J Clin Gastroenterol 1985; 7:354-360. (Pubitemid 15017149)
14. Osterreicher CH, Taura K, De Minicis S, et al. Angiotensin-converting- enzyme 2 inhibits liver fibrosis in mice. Hepatology 2009; 50:929-938.
15. Grace JA, Herath CB, Mak KY, et al. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) 2012; 123:225-239.
16. Park SW, Chen SW, Kim M, et al. Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. Lab Invest 2011; 91:63-84.
17. Park SW, Kim M, Brown KM, et al. Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology 2011; 53:1662-1675.
18. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48:2064-2077.
19. Du Cheyron D, Bouchet B, Parienti JJ, et al. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 2005; 31:1693-1699. (Pubitemid 41677246)
20. Barri YM, Sanchez EQ, Jennings LW, et al. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009; 15:475-483.
21. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231-1238. (Pubitemid 40469655)
22. Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinaseassociated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008; 52:425-433.
23. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinaseassociated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54:1012-1024.
24. McIlroy DR, Wagener G, Lee HT. Biomarkers of acute kidney injury: an evolving domain. Anesthesiology 2010; 112:998-1004.
25. Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57:2362-2370.
26. Niemann CU, Walia A, Waldman J, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009; 15:1852-1860.
27. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226. (Pubitemid 34827638)
28. Boudville N, Salama M, Jeffrey GP, Ferrari P. The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. Nephrol Dial Transplant 2009; 24:2926-2930.
29. Portal AJ, McPhail MJ, Bruce M, et al. Neutrophil gelatinase-associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl 2010; 16:1257-1266.
30. Wagener G, Minhaz M, Mattis FA, et al. Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant 2011; 26:1717-1723.
31. Tanaka T, Doi K, Maeda-Mamiya R, et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009; 174:1203-1211.
32. Li Y, Zhu M, Xia Q, et al. Urinary neutrophil gelatinase-associated lipocalin and L-type fatty acid binding protein as diagnostic markers of early acute kidney injury after liver transplantation. Biomarkers 2012; 17:336-342.
33. Wagener G, Kovalevskaya G, Minhaz M, et al. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2011; 25:665-670.
34. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, doubleblind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368. (Pubitemid 351615358)
35. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011; 55:315-321.
36. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012; 9:CD005162.
37. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010; 59:381-386.
38. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28:416-422. (Pubitemid 28363668)
39. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470. (Pubitemid 32119037)
40. Gonwa TA, McBride MA, Mai ML, Wadei HM. Kidney transplantation after previous liver transplantation: analysis of the organ procurement transplant network database. Transplantation 2011; 92:31-35.
41. Hibi T, Sageshima J, Molina E, et al. Predisposing factors of diminished survival in simultaneous liver/kidney transplantation. Am J Transplant 2012; 12:2966-2973.
42. Martin EF, Huang J, Xiang Q, et al. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl 2012; 18:914-929.
43. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11:1064-1072. (Pubitemid 41341755)
44. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9:327-336.
45. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11:965-976.
46. Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12:1755-1760. (Pubitemid 44920019)
47. Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007; 26:1195-1208. (Pubitemid 47620415)